Generic Name and Formulations:
Varicella zoster vaccine recombinant, adjuvanted; susp for IM inj after reconstitution (contains 50mcg of recombinant glycoprotein E antigen, 50mcg of monophosphoryl lipid A, and 50mcg of QS-21); per 0.5mL; preservative-free.
Indications for SHINGRIX:
Prevention of herpes zoster (shingles) in adults ≥50yrs of age.
Limitations Of use:
Not for preventing primary varicella infection (chickenpox).
<50yrs: not recommended. Give by IM inj in deltoid region of upper arm. ≥50yrs: one 0.5mL dose at Month 0 followed by second dose anytime between 2–6 months later. Administer immediately upon reconstitution or store refrigerated and use within 6hrs.
<18yrs: not established.
Allergies to any previous Shingrix vaccination.
Review immunization history prior to administration. Have appropriate medical treatment and supervision available to manage allergic reactions. Pregnancy. Nursing mothers.
Immunosuppressants may reduce efficacy of Shingrix. Concomitant inactivated influenza vaccines: see full labeling.
Local reactions (eg, pain, redness, swelling), myalgia, fatigue, headache, shivering, fever, GI symptoms.
To report adverse events, contact VAERS at (800) 822-7967.
Single-dose vials—1, 10 (antigen + adjuvant components)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline